Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
코로나19 예방을 위한 피하 REGEN-COV 항체 조합
Randomized Controlled Trial
[키워드] 1:1
acute respiratory syndrome
Administered
age
assigned
Asymptomatic
Combination
Contact
coronavirus
coronavirus disease
death
diagnosis of SARS-CoV-2
diagnostic
dose
efficacy end point
enrolled
high risk
Hospitalization
household contact
Immunity
Infection
Local
matching placebo
monoclonal antibody
participant
Participants
Placebo
Prevent
prevented
randomization
Randomly
receive
reduce
reduced
REGEN-COV
Regeneron Pharmaceutical
REGN-CoV2
resolution of symptom
risk
risk reduction
SARS-CoV-2
SARS-COV-2 infection
Seronegativity
shown
stratified
Subcutaneous
subcutaneous injection
subsequent
symptomatic
symptomatic and asymptomatic
symptomatic COVID-19
symptomatic disease
symptomatic SARS-CoV-2 infection
the median
the placebo group
toxic effect
uninfected
Viral load
[DOI] 10.1056/NEJMoa2109682 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1056/NEJMoa2109682 PMC 바로가기 [Article Type] Randomized Controlled Trial